OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
Mark G. Wise, James A. Karlowsky, Meredith Hackel, et al.
Microbial Drug Resistance (2023) Vol. 29, Iss. 8, pp. 360-370
Open Access | Times Cited: 20
Mark G. Wise, James A. Karlowsky, Meredith Hackel, et al.
Microbial Drug Resistance (2023) Vol. 29, Iss. 8, pp. 360-370
Open Access | Times Cited: 20
Showing 20 citing articles:
Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Pranita D. Tamma, Emily L. Heil, Julie Ann Justo, et al.
Clinical Infectious Diseases (2024)
Closed Access | Times Cited: 135
Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections
Petros I. Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 261-261
Open Access | Times Cited: 15
Petros I. Rafailidis, Periklis Panagopoulos, Christos Koutserimpas, et al.
Antibiotics (2024) Vol. 13, Iss. 3, pp. 261-261
Open Access | Times Cited: 15
In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 12
Anne Santerre Henriksen, Katy Jeannot, Antonio Oliver, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 4
Open Access | Times Cited: 12
In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)
Miki Takemura, Mark G. Wise, Meredith Hackel, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 8, pp. 2019-2027
Open Access | Times Cited: 17
Miki Takemura, Mark G. Wise, Meredith Hackel, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 8, pp. 2019-2027
Open Access | Times Cited: 17
Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model
Aliaa Fouad, Samantha Nicolau, Pranita D. Tamma, et al.
Infectious Diseases (2025), pp. 1-11
Closed Access
Aliaa Fouad, Samantha Nicolau, Pranita D. Tamma, et al.
Infectious Diseases (2025), pp. 1-11
Closed Access
Comment on: Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
Christopher Longshaw, Boudewijn L DeJonge, Yoshinori Yamano
Journal of Antimicrobial Chemotherapy (2025)
Open Access
Christopher Longshaw, Boudewijn L DeJonge, Yoshinori Yamano
Journal of Antimicrobial Chemotherapy (2025)
Open Access
TROJAN-MDR: in vitro activity of cefiderocol and comparators against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in Southern France, evaluation of available testing methods performances
Massinissa Benyahia, Chloé Magnan, Vincent Jean-Pierre, et al.
Annals of Clinical Microbiology and Antimicrobials (2025) Vol. 24, Iss. 1
Open Access
Massinissa Benyahia, Chloé Magnan, Vincent Jean-Pierre, et al.
Annals of Clinical Microbiology and Antimicrobials (2025) Vol. 24, Iss. 1
Open Access
Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study
Julián Torre‐Cisneros, Benito Almirante, Carmen Martos, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Open Access
Julián Torre‐Cisneros, Benito Almirante, Carmen Martos, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2025)
Open Access
Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye
Ecem Büyükyanbolu, Leyla Genc, Elizabeth A Cyr, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 9, pp. 1787-1794
Closed Access | Times Cited: 3
Ecem Büyükyanbolu, Leyla Genc, Elizabeth A Cyr, et al.
European Journal of Clinical Microbiology & Infectious Diseases (2024) Vol. 43, Iss. 9, pp. 1787-1794
Closed Access | Times Cited: 3
Effectiveness and Safety of Cefiderocol in Clinical Practice for Treatment of Patients with Gram-Negative Bacterial Infections: US Interim Results of the PROVE Study
Cornelius J. Clancy, Oliver A Cornely, Stephen W. Marcella, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4427-4443
Open Access | Times Cited: 3
Cornelius J. Clancy, Oliver A Cornely, Stephen W. Marcella, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4427-4443
Open Access | Times Cited: 3
A multicenter performance evaluation of cefiderocol MIC results: ComASP in comparison to CLSI broth microdilution
Laura Koeth, Jeanna DiFranco-Fisher, Elizabeth Palavecino, et al.
Journal of Clinical Microbiology (2024)
Closed Access | Times Cited: 3
Laura Koeth, Jeanna DiFranco-Fisher, Elizabeth Palavecino, et al.
Journal of Clinical Microbiology (2024)
Closed Access | Times Cited: 3
In vitro activity assessment of cefiderocol against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp., including β-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals
John H. Kimbrough, Joshua Maher, Hélio S. Sader, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 11
Open Access | Times Cited: 2
John H. Kimbrough, Joshua Maher, Hélio S. Sader, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 11
Open Access | Times Cited: 2
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates
Miki Takemura, Rio Nakamura, Merime Ota, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 12
Open Access | Times Cited: 5
Miki Takemura, Rio Nakamura, Merime Ota, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 12
Open Access | Times Cited: 5
Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy
Matteo Bassetti, Gianpaola Monti, Anne Santerre Henriksen, et al.
Antimicrobial Resistance and Infection Control (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Matteo Bassetti, Gianpaola Monti, Anne Santerre Henriksen, et al.
Antimicrobial Resistance and Infection Control (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study
John S. Bradley, Elaine Orchiston, Simon Portsmouth, et al.
The Pediatric Infectious Disease Journal (2024)
Closed Access | Times Cited: 1
John S. Bradley, Elaine Orchiston, Simon Portsmouth, et al.
The Pediatric Infectious Disease Journal (2024)
Closed Access | Times Cited: 1
Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?
Shio-Shin Jean, Chia‐Ying Liu, Tzu-Yu Huang, et al.
Expert Review of Anti-infective Therapy (2024), pp. 1-17
Closed Access | Times Cited: 1
Shio-Shin Jean, Chia‐Ying Liu, Tzu-Yu Huang, et al.
Expert Review of Anti-infective Therapy (2024), pp. 1-17
Closed Access | Times Cited: 1
Tackling the unyielding: testing two novel approaches against NDM-producing Enterobacterales and Pseudomonas aeruginosa isolates collected in India
Yamuna Devi Bakthavatchalam, Bijayini Behera, Anand Shah, et al.
Microbiology Spectrum (2024)
Open Access | Times Cited: 1
Yamuna Devi Bakthavatchalam, Bijayini Behera, Anand Shah, et al.
Microbiology Spectrum (2024)
Open Access | Times Cited: 1
Investigation of cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019–21
Kaan Kocer, Sébastien Boutin, Maximilian Moll, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 6
Open Access | Times Cited: 1
Kaan Kocer, Sébastien Boutin, Maximilian Moll, et al.
JAC-Antimicrobial Resistance (2024) Vol. 6, Iss. 6
Open Access | Times Cited: 1
TROJAN-MDR: In vitro activity of cefiderocol and comparators against multidrug-resistant Enterobacterales and Pseudomonas aeruginosa strains in Southern France, evaluation of available testing methods performances
Massinissa Benyahia, Chloé Magnan, V. Jean-Pierre, et al.
Research Square (Research Square) (2024)
Open Access
Massinissa Benyahia, Chloé Magnan, V. Jean-Pierre, et al.
Research Square (Research Square) (2024)
Open Access
The challenges of difficult-to-treat Acinetobacter infections
Guy A. Richards, Olga Perovic, Adrian Brink
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 4
Closed Access
Guy A. Richards, Olga Perovic, Adrian Brink
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 4
Closed Access
